Next Article in Journal
Optimization of Predictive Performance for the Therapeutic Response Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma
Next Article in Special Issue
Contralateral Liver Hypertrophy and Oncological Outcome Following Radioembolization with 90Y-Microspheres: A Systematic Review
Previous Article in Journal
CD147 Promotes Cell Small Extracellular Vesicles Release during Colon Cancer Stem Cells Differentiation and Triggers Cellular Changes in Recipient Cells
Open AccessReview

Extracellular Vesicles, A Possible Theranostic Platform Strategy for Hepatocellular Carcinoma—An Overview

1
National Research Council (CNR), Institute for Biomedical Technologies (ITB), 20090 Segrate, Milan, Italy
2
Department of Hematology, Transfusion Medicine and Biotechnologies, Laboratory of Stem Cells, Spirito Santo Hospital, 65125 Pescara, Italy
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(2), 261; https://doi.org/10.3390/cancers12020261
Received: 23 December 2019 / Revised: 13 January 2020 / Accepted: 16 January 2020 / Published: 21 January 2020
(This article belongs to the Special Issue Liver Interventional Oncology)
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third highest cause of mortality from cancer, largely because of delays in diagnosis. There is currently no effective therapy for advanced stage HCC, although sorafenib, the standard treatment for HCC, systemic therapy (including tyrosine kinase inhibitors and anti-angiogenesis agents), and more recently, immunotherapy, have demonstrated some survival benefit. The measurement and modification of extracellular vesicle (EVs) cargoes—composed of nucleic acids, including miRNAs, proteins, and lipids—holds great promise for future HCC diagnosis, prognosis, and treatment. This review will provide an overview of the most recent findings regarding EVs in HCC, and the possible future use of EVs as “liquid biopsy”-based biomarkers for early diagnosis and as a vehicle for targeted drug-delivery. View Full-Text
Keywords: hepatocellular carcinoma; extracellular vesicles; liquid biopsy; drug delivery hepatocellular carcinoma; extracellular vesicles; liquid biopsy; drug delivery
Show Figures

Figure 1

MDPI and ACS Style

D’Agnano, I.; Berardi, A.C. Extracellular Vesicles, A Possible Theranostic Platform Strategy for Hepatocellular Carcinoma—An Overview. Cancers 2020, 12, 261.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop